MRNA Live signals | Maximize Profits with Getagraph.com

SELL 385 min ago

@ $105.56

Issued: 25 Apr 2024 @ 13:42

Return: 0.59%

Previous signal: Apr 25 - 09:30

Previous signal: Buy

Return: -1.79 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	2.74M
Average Volume	3.78M
Market Cap	40.65B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-3.40 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.61
ATR14	$4.65 (4.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Afeyan Noubar	Sell	8 243	Common Stock
2024-04-17	Afeyan Noubar	Sell	6 475	Common Stock
2024-04-17	Afeyan Noubar	Sell	282	Common Stock
2024-04-15	Hoge Stephen	Sell	15 000	Common Stock
2024-04-10	Afeyan Noubar	Sell	6 351	Common Stock

INSIDER POWER
31.48
Last 100 transactions
Buy: 525 652 \| Sell: 276 824

Volume Correlation

Long: 0.38 (neutral)

Short: 0.04 (neutral)

Signal:(57) Neutral

Moderna Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Moderna Inc Correlation - Currency/Commodity

-0.74
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

-0.07
( neutral )

0.06
( neutral )

0.51
( weak )

Moderna Inc Financials

Annual	2023
Revenue:	$6.75B
Gross Profit:	$2.06B (30.52 %)
EPS:	$-12.34

Q4	2023
Revenue:	$2.81B
Gross Profit:	$1.88B (66.97 %)
EPS:	$0.570

Q3	2023
Revenue:	$1.83B
Gross Profit:	$-410.00M (-22.39 %)
EPS:	$-9.53

Q2	2023
Revenue:	$344.00M
Gross Profit:	$-387.00M (-112.50 %)
EPS:	$-3.62

Financial Reports:

No articles found.

Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.